Janux Therapeutics

JANUX THERAPEUTICS INC

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Victorias Secre, Easton, OH

Mid Cap

News

Movers

Trading Ideas

ASAN

BTDR

FIVE

JANX

NBIS

NVCR

SOUN

VSCO

ZETA

Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.

SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?

bz_pharma_briefs

Analyst Color

Biotech

Health Care

Analyst Ratings

General

Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients.

Janux Therapeutics&#39; Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

ATT.AT&T

AAOI

AOSL

BBAI

CRDO

PRCH

UXIN

AT&amp;T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday

Janux Therapeutics Inc

Press Releases

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Clear Street Launches Healthcare & Biotechnology Equity Research

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

MLTX

NUVB

PTGX

YMAB

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

Gyre Therapeutics

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

Arcus Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

ARS Pharmaceuticals

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

HC Wainwright & Co.

Scotiabank

Cantor Fitzgerald

Stifel

Leerink Partners

Comments

Janux Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell